Bruce A Berkowitz1, Timothy S Kern2, David Bissig3, Priya Patel3, Ankit Bhatia3, Vladimir J Kefalov4, Robin Roberts3. 1. Department of Anatomy and Cell Biology Wayne State University School of Medicine, Detroit, Michigan, United States 2Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan, United States. 2. Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio, United States. 3. Department of Anatomy and Cell Biology Wayne State University School of Medicine, Detroit, Michigan, United States. 4. Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States.
Abstract
PURPOSE: Diabetes appears to induce a visual cycle defect because rod dysfunction is correctable with systemic treatment of the visual cycle chromophore 11-cis-retinaldehyde. However, later studies have found no evidence for visual cycle impairment. Here, we further examined whether photoreceptor dysfunction is corrected with 11-cis-retinaldehyde. Because antioxidants correct photoreceptor dysfunction in diabetes, the hypothesis that exogenous visual chromophores have antioxidant activity in the retina of diabetic mice in vivo was tested. METHODS: Rod function in 2-month-old diabetic mice was evaluated using transretinal electrophysiology in excised retinas and apparent diffusion coefficient (ADC) MRI to measure light-evoked expansion of subretinal space (SRS) in vivo. Optokinetic tracking was used to evaluate cone-based visual performance. Retinal production of superoxide free radicals, generated mostly in rod cells, was biochemically measured with lucigenin. Diabetic mice were systemically treated with a single injection of either 11-cis-retinaldehyde, 9-cis-retinaldehyde (a chromophore surrogate), or all-trans-retinaldehyde (the photoisomerization product of 11-cis-retinaldehyde). RESULTS: Consistent with previous reports, diabetes significantly reduced (1) dark-adapted rod photo responses (transretinal recording) by ∼18%, (2) rod-dominated light-stimulated SRS expansion (ADC MRI) by ∼21%, and (3) cone-dominated contrast sensitivity (using optokinetic tracking [OKT]) by ∼30%. Both 11-cis-retinaldehyde and 9-cis-retinaldehyde largely corrected these metrics of photoreceptor dysfunction. Higher-than-normal retinal superoxide production in diabetes by ∼55% was also significantly corrected following treatment with 11-cis-retinaldehyde, 9-cis-retinaldehyde, or all-trans-retinaldehyde. CONCLUSIONS: Collectively, data suggest that retinaldehydes improve photoreceptor dysfunction in diabetic mice, independent of the visual cycle, via an antioxidant mechanism.
PURPOSE:Diabetes appears to induce a visual cycle defect because rod dysfunction is correctable with systemic treatment of the visual cycle chromophore 11-cis-retinaldehyde. However, later studies have found no evidence for visual cycle impairment. Here, we further examined whether photoreceptor dysfunction is corrected with 11-cis-retinaldehyde. Because antioxidants correct photoreceptor dysfunction in diabetes, the hypothesis that exogenous visual chromophores have antioxidant activity in the retina of diabeticmice in vivo was tested. METHODS: Rod function in 2-month-old diabeticmice was evaluated using transretinal electrophysiology in excised retinas and apparent diffusion coefficient (ADC) MRI to measure light-evoked expansion of subretinal space (SRS) in vivo. Optokinetic tracking was used to evaluate cone-based visual performance. Retinal production of superoxide free radicals, generated mostly in rod cells, was biochemically measured with lucigenin. Diabeticmice were systemically treated with a single injection of either 11-cis-retinaldehyde, 9-cis-retinaldehyde (a chromophore surrogate), or all-trans-retinaldehyde (the photoisomerization product of 11-cis-retinaldehyde). RESULTS: Consistent with previous reports, diabetes significantly reduced (1) dark-adapted rod photo responses (transretinal recording) by ∼18%, (2) rod-dominated light-stimulated SRS expansion (ADC MRI) by ∼21%, and (3) cone-dominated contrast sensitivity (using optokinetic tracking [OKT]) by ∼30%. Both 11-cis-retinaldehyde and 9-cis-retinaldehyde largely corrected these metrics of photoreceptor dysfunction. Higher-than-normal retinal superoxide production in diabetes by ∼55% was also significantly corrected following treatment with 11-cis-retinaldehyde, 9-cis-retinaldehyde, or all-trans-retinaldehyde. CONCLUSIONS: Collectively, data suggest that retinaldehydes improve photoreceptor dysfunction in diabeticmice, independent of the visual cycle, via an antioxidant mechanism.
Authors: J Emanuel Ramos de Carvalho; Frank D Verbraak; Maurice C Aalders; Cornelis J van Noorden; Reinier O Schlingemann Journal: Surv Ophthalmol Date: 2013-10-03 Impact factor: 6.048
Authors: Chieh Allen Lee; Guangyuan Li; Mansi D Patel; J Mark Petrash; Beth Ann Benetz; Alex Veenstra; Jaume Amengual; Johannes von Lintig; Christopher J Burant; Johnny Tang; Timothy S Kern Journal: Invest Ophthalmol Vis Sci Date: 2014-05-02 Impact factor: 4.799
Authors: X W Mao; M Boerma; D Rodriguez; M Campbell-Beachler; T Jones; S Stanbouly; V Sridharan; N C Nishiyama; A Wroe; G A Nelson Journal: Radiat Res Date: 2018-11-15 Impact factor: 2.841
Authors: Bruce A Berkowitz; Robert H Podolsky; Karen M Lins-Childers; Yichao Li; Haohua Qian Journal: Invest Ophthalmol Vis Sci Date: 2019-04-01 Impact factor: 4.925
Authors: Bruce A Berkowitz; Robert H Podolsky; Karen Lins Childers; Robin Roberts; Michael Schneider; Emma Graffice; Kenan Sinan; Ali Berri; Lamis Harp Journal: Invest Ophthalmol Vis Sci Date: 2021-05-03 Impact factor: 4.799